华西口腔医学杂志

• 临床研究 • 上一篇    下一篇

三联化疗在口腔鳞癌综合治疗中的应用及其疗效评价

刘曙光,廖楚航,王大章,赵建江,艾伟健,郑俊发   

  1. 610041 四川大学华西口腔医院口腔颌面外科(刘曙光,廖楚航,王大章),广东省口腔医院(赵建江,艾伟健,郑俊发)
  • 收稿日期:2003-04-25 修回日期:2003-04-25 出版日期:2003-04-20 发布日期:2003-04-20
  • 基金资助:
    本课题为广东省卫生厅科研基金资助项目(编号A20001094)

The Clinical Application and Evaluation of Combined Chemotherapy in Comprehensive Treatment for Oral Squamous Cell Carcinoma

LIUShuguang,LIAO Chuhang,WANG Dazhang,et al.   

  1. West China College of Stomatology,Sichuan University,Chengdu 610041,China
  • Received:2003-04-25 Revised:2003-04-25 Online:2003-04-20 Published:2003-04-20

摘要:

目的 评价术前三联化疗(PYM+5-Fu+DDP)配合手术治疗口腔鳞癌的临床疗效及与多药耐药性的关系。方法 采用术前三联化疗合并手术综合方案治疗口腔鳞癌患者102例,全部患者均经活检确诊。对所有患者的化疗效果进行评价,并对综合治疗的效果进行随访观察。结果 102例患者化疗有效率为82·4%。有完整随访资料者92例,存活69例,3年生存率为67·6%。结论 本三联化疗方案在口腔鳞癌综合治疗中具有用药剂量小、疗效确切等优点,可作为口腔鳞癌患者术前化疗方案之一。

关键词: 化疗, 口腔鳞癌, 多药耐药性

Abstract:

Objective To study and evaluate the clinical effects of combined preoperative chemotherapy and their rela- tionswith multi drug resistance (MDR).Methods 102 cases with oral squamous cell carcinoma(OSCC) were included in the study (63 males and 39 females,aged 22 to 67 years). Amongthe subjects therewere 57 caseswith cancer of tongue and 45 cases with cancer of buccal mucosa.27 cases in the groupwere classified as stageⅡ,55 as stageⅢand 20 cases as stageⅣaccording to TNMstandard.All cases accepted PYM+5-Fu+DDP combined chemotherapy pre-operatively.The total given dosewas PYM48 mg,5-Fu 7·5 g and DDP300 mg.Afterthe chemotherapy,radical surgerywere performedwithin 2 weeks.The diagnosis of all cases were proved as OSCC by biopsy.Results Total effective rate of the combined chemotherapy was 82·4%. All of the cases were followed up and their 3 years′survival rate was 67·6%.Conclusion The combined chemotherapy of PYM+5-Fu+DDP is ef- fective in using as one of comprehensive treatment for OSCC.

Key words: chemotherapy, oral squamous cell carcinoma, multi drug resistance